Skip to main content
. 2020 Sep 17;20:371. doi: 10.1186/s12886-020-01637-0

Table 4.

Additional responder patients, injections and incremental costs (6-month induction vs 3-month induction)

6-month induction vs
3-month induction
Additional responder patients Additional injections Incremental treatment costs
Aflibercept (Eylea®) 36.52 289.57 €214,862.57
Ranibizumab (Lucentis®) 20.66 280.98 €208,488.98
Bevacizumab (Avastin®) 13.19 393.56 €134,483.16
TOTAL 70.37 964.11 €557,834.71